In the present study, rADCmin could effectively differentiate MGMT promoter methylation status in the IDH wild-type subgroup (AUC = 0.78), leading us to hypothesize that IDH wild-type gliomas have more significant differences in ADC values due to higher cellular heterogeneity and necrotic tendency. This evidence concerns the gene IDH2 and central nervous system cancer.